May 6, 2020 / 11:45 PM / a month ago

BRIEF-Innovent Biologics Updates On Phase 3 ORIENT-12 Study On Squamous NSCLC

May 7 (Reuters) - Innovent Biologics Inc:

* UPDATES ON PHASE 3 ORIENT-12 STUDY INVESTIGATING TYVYT IN COMBINATION WITH GEMZAR & PLATINUM CHEMOTHERAPY FOR SQUAMOUS NSCLC

* PHASE 3 ORIENT-12 STUDY IN CHINA INVESTIGATING TYVYT MET PREDEFINED PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL

* CO & ELI LILLY TO INITIATE REGULATORY DISCUSSIONS FOR REGISTRATION WITH NMPA OF CHINA IN NEAR FUTURE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below